With a median follow-up of 84.7 months, the addition of ibrutinib to bendamustine/rituximab and rituximab maintenance improved progression-free survival by what percentage vs placebo?

CategoriesView All Quizzes

Tumor Type

• Breast Cancer
• Gastrointestinal Cancers
• Genitourinary Cancers
• Gynecologic Cancers
• Head & Neck/Thyroid Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Melanoma
• Multiple Myeloma

Additional Topics

• COVID-19
• Oncology History
• Supportive Care

Conference Coverage

• 2024 ASH Annual Meeting & Exposition
• 2021 ASH Annual Meeting & Exposition
• 2021 San Antonio Breast Cancer Symposium
• 2022 ASCO Annual Meeting
• 2022 ASCO Gastrointestinal Cancers Symposium
• 2022 ASCO Genitourinary Cancers Symposium
• 2022 ASCO Quality Care Symposium
• 2022 ASH Annual Meeting and Exposition
• 2022 Multidisciplinary Head and Neck Cancers Symposium
• 2022 San Antonio Breast Cancer Symposium
• 2023 ASCO Annual Meeting
• 2023 ASCO Gastrointestinal Cancers Symposium
• 2023 ASCO Genitourinary Cancers Symposium
• 2023 ASH Annual Meeting and Exposition
• 2023 San Antonio Breast Cancer Symposium
• 2024 ASCO Annual Meeting
• 2024 ASCO Gastrointestinal Cancers Symposium
• 2024 ASCO Genitourinary Cancers Symposium
• 2025 ASCO Gastrointestinal Cancers Symposium
• 2025 ASCO Genitourinary Cancers Symposium
• AACR Annual Meeting 2022
• AACR Annual Meeting 2023
• ASTRO Annual Meeting 2022
• ESMO Congress 2022
• ESMO Congress 2023
• ESMO Congress 2024